Distinct Prognostic Values of Four-Notch-receptor MRNA Expression in Ovarian Cancer

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Dec 15

PMID 26662955

Citations 14

Authors

Xinling Zhou

Lingling Teng

Min Wang

Affiliations

Soon will be listed here.

Abstract

Notch signaling pathway includes ligands and Notch receptors, which are frequently deregulated in several human malignancies including ovarian cancer. Aberrant activation of Notch signaling has been linked to ovarian carcinogenesis and progression. In the current study, we used the "Kaplan-Meier plotter" (KM plotter) database, in which updated gene expression data and survival information from a total of 1306 ovarian cancer patients were used to access the prognostic value of four Notch receptors in ovarian cancer patients. Hazard ratio (HR), 95 % confidence intervals, and log-rank P were calculated. Notch1 messenger RNA (mRNA) high expression was not found to be correlated to overall survival (OS) for all ovarian cancer, as well as in serous and endometrioid cancer patients followed for 20 years. However, Notch1 mRNA high expression is significantly associated with worsen OS in TP53 wild-type ovarian cancer patients, while it is significantly associated with better OS in TP53 mutation-type ovarian cancer patients. Notch2 mRNA high expression was found to be significantly correlated to worsen OS for all ovarian cancer patients, as well as in grade II ovarian cancer patients. Notch3 mRNA high expression was found to be significantly correlated to better OS for all ovarian cancer patients, but not in serous cancer patients and endometrioid cancer patients. Notch4 mRNA high expression was not found to be significantly correlated to OS for all ovarian cancer patients, serous cancer patients, and endometrioid cancer patients. These results indicate that there are distinct prognostic values of four Notch receptors in ovarian cancer. This information will be useful for better understanding of the heterogeneity and complexity in the molecular biology of ovarian cancer and for developing tools to more accurately predict their prognosis. Based on our results, Notch1 could be a potential drug target of TP53 wild-type ovarian cancer and Notch2 could be a potential drug target of ovarian cancer.

Citing Articles

The Clinical Application of Immunohistochemical Expression of Notch4 Protein in Patients with Colon Adenocarcinoma.

Brzozowa-Zasada M, Piecuch A, Michalski M, Matysiak N, Kucharzewski M, Los M Int J Mol Sci. 2023; 24(8).

PMID: 37108670 PMC: 10138794. DOI: 10.3390/ijms24087502.

Claudin-4 localization in epithelial ovarian cancer.

Neville M, Webb P, Baumgartner H, Bitler B Heliyon. 2022; 8(10):e10862.

PMID: 36237976 PMC: 9552118. DOI: 10.1016/j.heliyon.2022.e10862.

Functional Gene Expression Differentiation of the Notch Signaling Pathway in Female Reproductive Tract Tissues-A Comprehensive Review With Analysis.

Orzechowska M, Anusewicz D, Bednarek A Front Cell Dev Biol. 2021; 8:592616.

PMID: 33384996 PMC: 7770115. DOI: 10.3389/fcell.2020.592616.

Distinct functions and prognostic values of RORs in gastric cancer.

Gu F, Liu Y, Liu Y, Cheng S, Yang J, Kang M Open Med (Wars). 2020; 15(1):424-434.

PMID: 33336001 PMC: 7711859. DOI: 10.1515/med-2020-0406.

Distinct prognostic values and antitumor effects of tumor growth factor β1 and its receptors in gastric cancer.

Liu F, Wang H, Zhang M Oncol Lett. 2020; 20(3):2621-2632.

PMID: 32782580 PMC: 7400994. DOI: 10.3892/ol.2020.11849.

References

Miele L . Notch signaling. Clin Cancer Res. 2006; 12(4):1074-9. DOI: 10.1158/1078-0432.CCR-05-2570. View

Zhou C, Zhong Q, Rhodes L, Townley I, Bratton M, Zhang Q . Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012; 14(2):R45. PMC: 3446379. DOI: 10.1186/bcr3144. View

Adam Maciejczyk A . New prognostic factors in breast cancer. Adv Clin Exp Med. 2013; 22(1):5-15. View

Brown C, Brodsky A, Freiman R . Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2. Mol Cancer Res. 2014; 13(1):78-85. PMC: 4312524. DOI: 10.1158/1541-7786.MCR-14-0334. View

Foley O, Rauh-Hain J, Carmen M . Recurrent epithelial ovarian cancer: an update on treatment. Oncology (Williston Park). 2013; 27(4):288-94, 298. View

Gao M, Choi Y, Kang S, Youn J, Cho N . CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010; 29(18):2672-80. DOI: 10.1038/onc.2010.35. View

Jhappan C, Gallahan D, Stahle C, Chu E, Smith G, Merlino G . Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev. 1992; 6(3):345-55. DOI: 10.1101/gad.6.3.345. View

Hong C, Zhang F, You Y, Qiu W, Giuliano A, Cui X . Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study. BMC Cancer. 2015; 15:548. PMC: 4513615. DOI: 10.1186/s12885-015-1569-2. View

Soriano J, Uyttendaele H, Kitajewski J, Montesano R . Expression of an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitro. Int J Cancer. 2000; 86(5):652-9. DOI: 10.1002/(sici)1097-0215(20000601)86:5<652::aid-ijc8>3.0.co;2-v. View

10.

Yen W, Fischer M, Axelrod F, Bond C, Cain J, Cancilla B . Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015; 21(9):2084-95. DOI: 10.1158/1078-0432.CCR-14-2808. View

11.

Callahan R, Raafat A . Notch signaling in mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia. 2001; 6(1):23-36. DOI: 10.1023/a:1009512414430. View

12.

Alniaimi A, Demorest-Hayes K, Alexander V, Seo S, Yang D, Rose S . Increased Notch1 expression is associated with poor overall survival in patients with ovarian cancer. Int J Gynecol Cancer. 2015; 25(2):208-13. DOI: 10.1097/IGC.0000000000000359. View

13.

Park J, Li M, Nakayama K, Mao T, Davidson B, Zhang Z . Notch3 gene amplification in ovarian cancer. Cancer Res. 2006; 66(12):6312-8. DOI: 10.1158/0008-5472.CAN-05-3610. View

14.

Leung P, Choi J . Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update. 2006; 13(2):143-62. DOI: 10.1093/humupd/dml002. View

15.

Lewis J . Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol. 1999; 9(6):583-9. DOI: 10.1006/scdb.1998.0266. View

16.

Ivanova L, Zandberga E, Silina K, Kalnina Z, Abols A, Endzelins E . Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. Cancer Chemother Pharmacol. 2014; 75(2):235-46. DOI: 10.1007/s00280-014-2635-1. View

17.

Liu M, Wang G, Gomez-Fernandez C, Guo S . GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancer. PLoS One. 2012; 7(10):e46410. PMC: 3463574. DOI: 10.1371/journal.pone.0046410. View

18.

Wang H, Huang X, Zhang J, Shao N, Chen L, Ma D . The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clin Chim Acta. 2014; 436:243-8. DOI: 10.1016/j.cca.2014.06.005. View

19.

Kopan R, Ilagan M . The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009; 137(2):216-33. PMC: 2827930. DOI: 10.1016/j.cell.2009.03.045. View

20.

Wu S, Xue W, Huang X, Yu X, Luo M, Huang Y . Distinct prognostic values of ALDH1 isoenzymes in breast cancer. Tumour Biol. 2015; 36(4):2421-6. DOI: 10.1007/s13277-014-2852-6. View